Detalhe da pesquisa
1.
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Appl Health Econ Health Policy
; 8(5): 301-15, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20804223
2.
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.
Clinicoecon Outcomes Res
; 9: 31-38, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28115857
3.
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Clinicoecon Outcomes Res
; 8: 475-484, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27703384